{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:26:20Z","timestamp":1792801580173,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82322030"],"award-info":[{"award-number":["82322030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Projects in Guangzhou","award":["2025A03J4201"],"award-info":[{"award-number":["2025A03J4201"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501100"],"award-info":[{"award-number":["2023ZD0501100"]}]},{"name":"the Major Research Plan of the National Natural Science Foundation of China","award":["92359302"],"award-info":[{"award-number":["92359302"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangdong Provincial Clinical Research Center for Breast Diseases","award":["2023B110005"],"award-info":[{"award-number":["2023B110005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03556-6","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:52Z","timestamp":1766400412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tertiary lymphoid structures are associated with lower axillary residual nodal burden in breast cancer patients after neoadjuvant chemotherapy"],"prefix":"10.1186","volume":"30","author":[{"given":"Zhihao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konglan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanle","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"12","key":"3556_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717\u201334.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3556_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"2","key":"3556_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2025.02.12","volume":"37","author":"H Liu","year":"2025","unstructured":"Liu H, Dilger JP. Different strategies for cancer treatment: targeting cancer cells or their neighbors? Chin J Cancer Res. 2025;37(2):289\u201392.","journal-title":"Chin J Cancer Res"},{"key":"3556_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286-287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324.","journal-title":"Cancer Genet"},{"issue":"6","key":"3556_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345\u201359.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3556_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237\u201351.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3556_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13046-020-01788-4","volume":"40","author":"H Huang","year":"2021","unstructured":"Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, et al. The immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res. 2021;40(1):19.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3556_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-025-02270-5","volume":"24","author":"L Maksymova","year":"2025","unstructured":"Maksymova L, Pilger YA, Nuhn L, Van Ginderachter JA. Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines. Mol Cancer. 2025;24(1):65.","journal-title":"Mol Cancer"},{"issue":"6","key":"3556_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3556_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41568-024-00681-y","volume":"24","author":"T Karakousi","year":"2024","unstructured":"Karakousi T, Mudianto T, Lund AW. Lymphatic vessels in the age of cancer immunotherapy. Nat Rev Cancer. 2024;24(6):363\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"6576","key":"3556_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419.","journal-title":"Science"},{"issue":"7791","key":"3556_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556\u201360.","journal-title":"Nature"},{"issue":"7791","key":"3556_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355.","journal-title":"Nature"},{"issue":"6","key":"3556_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2020.02.015","volume":"180","author":"Y Lu","year":"2020","unstructured":"Lu Y, Zhao Q, Liao JY, Song E, Xia Q, Pan J, et al. Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. Cell. 2020;180(6):1081-97.e24.","journal-title":"Cell"},{"issue":"6","key":"3556_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00262-022-03353-8","volume":"72","author":"S Wakasu","year":"2023","unstructured":"Wakasu S, Tagawa T, Haratake N, Kinoshita F, Oku Y, Ono Y, et al. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. Cancer Immunol Immunother. 2023;72(6):1823\u201334.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3556_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","volume":"23","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A, et al. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application. Mol Cancer. 2024;23(1):75.","journal-title":"Mol Cancer"},{"issue":"1","key":"3556_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"EBCTCG","year":"2018","unstructured":"EBCTCG. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339.","journal-title":"Lancet Oncol"},{"issue":"14","key":"3556_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA"},{"issue":"9938","key":"3556_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"12","key":"3556_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3556_CR21","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park YH, Lal S, Lee JE, Choi YL, Wen J, Ram S, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020;11(1):6175.","journal-title":"Nat Commun"},{"issue":"1","key":"3556_CR22","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1038\/s41467-024-47932-y","volume":"15","author":"K Wang","year":"2024","unstructured":"Wang K, Zerdes I, Johansson HJ, Sarhan D, Sun Y, Kanellis DC, et al. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer. Nat Commun. 2024;15(1):3837.","journal-title":"Nat Commun"},{"issue":"8","key":"3556_CR23","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-07-4491","volume":"14","author":"S Ladoire","year":"2008","unstructured":"Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008;14(8):2413\u201320.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3556_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s13058-014-0488-5","volume":"16","author":"E Garc\u00eda-Mart\u00ednez","year":"2014","unstructured":"Garc\u00eda-Mart\u00ednez E, Gil GL, Benito AC, Gonz\u00e1lez-Billalabeitia E, Conesa MA, Garc\u00eda Garc\u00eda T, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3556_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1078-0432.CCR-24-1594","volume":"31","author":"T Lanickova","year":"2025","unstructured":"Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, et al. Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer. Clin Cancer Res. 2025;31(1):164\u201380.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3556_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1583547","volume":"8","author":"G Morcrette","year":"2019","unstructured":"Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, et al. APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncoimmunology. 2019;8(6):e1583547.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3556_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12957-025-03796-0","volume":"23","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhang C, Hou Y, Zhao B, Cui B. Correlation analysis of tertiary lymphoid structure parameters with the prognosis of patients with locally advanced rectal cancer after neoadjuvant chemotherapy: a retrospective study. World J Surg Oncol. 2025;23(1):131.","journal-title":"World J Surg Oncol"},{"key":"3556_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005531","author":"X Sun","year":"2022","unstructured":"Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005531.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"3556_CR29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2(8):794\u2013802.","journal-title":"Nat Cancer"},{"issue":"5","key":"3556_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100063","volume":"103","author":"L Vanhersecke","year":"2023","unstructured":"Vanhersecke L, Bougouin A, Cromb\u00e9 A, Brunet M, Sofeu C, Parrens M, et al. Standardized pathology screening of mature tertiary lymphoid structures in cancers. Lab Invest. 2023;103(5):100063.","journal-title":"Lab Invest"},{"issue":"1","key":"3556_CR31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1186\/s12885-020-07696-2","volume":"20","author":"W Ma","year":"2020","unstructured":"Ma W, Yang J, Liu N, Pu X, Qu F, Xu L, et al. Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma? BMC Cancer. 2020;20(1):1182.","journal-title":"BMC Cancer"},{"key":"3556_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-1-0716-2059-5_14","volume":"2441","author":"SG Martin","year":"2022","unstructured":"Martin SG, Rakha E, Storr SJ. Quantifying lymphatic vessel density in human tissue samples. Methods Mol Biol. 2022;2441:183\u20139.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"3556_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pros.21225","volume":"71","author":"CG van Niekerk","year":"2011","unstructured":"van Niekerk CG, van de Hulsbergen- Kaa CA, Barentsz JO, Witjes JA, van der Laak JA. Quantitative analysis of lymph vessel characteristics in organ confined prostate cancer. Prostate. 2011;71(1):91\u20137.","journal-title":"Prostate"},{"issue":"6","key":"3556_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40(6):609-23.e6.","journal-title":"Cancer Cell"},{"issue":"12","key":"3556_CR35","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.2010.31.2231","volume":"29","author":"C Desmedt","year":"2011","unstructured":"Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29(12):1578\u201386.","journal-title":"J Clin Oncol"},{"issue":"7894","key":"3556_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"SJ Sammut","year":"2022","unstructured":"Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature. 2022;601(7894):623\u20139.","journal-title":"Nature"},{"issue":"21","key":"3556_CR37","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1158\/1078-0432.CCR-19-3685","volume":"26","author":"ML Axelrod","year":"2020","unstructured":"Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, et al. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer. Clin Cancer Res. 2020;26(21):5668\u201381.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3556_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41698-024-00533-w","volume":"8","author":"Q Wang","year":"2024","unstructured":"Wang Q, Zhong W, Shen X, Hao Z, Wan M, Yang X, et al. Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer. NPJ Precis Oncol. 2024;8(1):61.","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"3556_CR39","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26(12):1845\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"3556_CR40","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun. 2024;15(1):2528.","journal-title":"Nat Commun"},{"issue":"42","key":"3556_CR41","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1038\/onc.2011.602","volume":"31","author":"A Alitalo","year":"2012","unstructured":"Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene. 2012;31(42):4499\u2013508.","journal-title":"Oncogene"},{"issue":"3","key":"3556_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3677","volume":"14","author":"SA Stacker","year":"2014","unstructured":"Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer. 2014;14(3):159\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3556_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1346","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang Q, Sun K, Liu R, Song Y, Lv Y, Bi P, et al. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy. Clin Transl Med. 2023;13(8):e1346.","journal-title":"Clin Transl Med"},{"issue":"6","key":"3556_CR44","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/cas.14023","volume":"110","author":"S Kuwabara","year":"2019","unstructured":"Kuwabara S, Tsuchikawa T, Nakamura T, Hatanaka Y, Hatanaka KC, Sasaki K, et al. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Cancer Sci. 2019;110(6):1853\u201362.","journal-title":"Cancer Sci"},{"key":"3556_CR45","doi-asserted-by":"publisher","first-page":"1499731","DOI":"10.3389\/fimmu.2024.1499731","volume":"15","author":"C Yang","year":"2024","unstructured":"Yang C, You J, Wang Y, Chen S, Tang Y, Chen H, et al. TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC. Front Immunol. 2024;15:1499731.","journal-title":"Front Immunol"},{"issue":"25","key":"3556_CR46","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"7","key":"3556_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"32","key":"3556_CR48","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"EP Mamounas","year":"2012","unstructured":"Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3556_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156(6):e210891.","journal-title":"JAMA Surg"},{"issue":"1","key":"3556_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-024-07334-6","volume":"207","author":"K Chin","year":"2024","unstructured":"Chin K, Land\u00e9n AH, Kov\u00e1cs A, W\u00e4rnberg F, Ekholm M, Karlsson P, et al. Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study. Breast Cancer Res Treat. 2024;207(1):49\u201363.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3556_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3556_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102071","volume":"104","author":"YJ Cho","year":"2024","unstructured":"Cho YJ, Hwang I, Park S, Lee S, Kang SY, Kim MJ, et al. Prognostic effect of tertiary lymphoid structures in Epstein-Barr virus-associated gastric carcinomas measured by digital image analysis. Lab Invest. 2024;104(7):102071.","journal-title":"Lab Invest"},{"issue":"2","key":"3556_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/odi.15080","volume":"31","author":"M Yao","year":"2025","unstructured":"Yao M, Yang T, Li Q, Zhang X, Zheng Z, Li J, et al. Characteristics and clinical significance of tertiary lymphoid structures in OSCC. Oral Dis. 2025;31(2):387\u2013400.","journal-title":"Oral Dis"},{"issue":"1","key":"3556_CR54","first-page":"028","volume":"6","author":"H Liu","year":"2020","unstructured":"Liu H. Nav channels in cancers: Non-classical roles. Glob J Cancer Ther. 2020;6(1):028\u201332.","journal-title":"Glob J Cancer Ther"},{"key":"3556_CR55","doi-asserted-by":"publisher","DOI":"10.26717\/BJSTR.2020.25.004166","author":"H Liu","year":"2020","unstructured":"Liu H. A prospective for the potential effect of local anesthetics on stem-like cells in colon cancer. Biomed J Sci & Tech Res. 2020. https:\/\/doi.org\/10.26717\/BJSTR.2020.25.004166.","journal-title":"Biomed J Sci & Tech Res"},{"key":"3556_CR56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241799","author":"X Geng","year":"2025","unstructured":"Geng X, Chen L, Ahmed Z, Formigari GP, Ho YC, Del Gaudio I, et al. S1PR1 regulates lymphatic valve development and tertiary lymphoid organ formation in the ileum. J Exp Med. 2025. https:\/\/doi.org\/10.1084\/jem.20241799.","journal-title":"J Exp Med"},{"issue":"4","key":"3556_CR57","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/1574892817666220119121204","volume":"17","author":"Z Jin","year":"2022","unstructured":"Jin Z, Zhang W, Liu H, Ding A, Lin Y, Wu SX, et al. Potential therapeutic application of local anesthetics in cancer treatment. Recent Pat Anticancer Drug Discov. 2022;17(4):326\u201342.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"3","key":"3556_CR58","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.breast.2015.02.034","volume":"24","author":"S Tsuyuki","year":"2015","unstructured":"Tsuyuki S, Yamaguchi A, Kawata Y, Kawaguchi K. Assessing the effects of neoadjuvant chemotherapy on lymphatic pathways to sentinel lymph nodes in cases of breast cancer: usefulness of the indocyanine green-fluorescence method. Breast. 2015;24(3):298\u2013301.","journal-title":"Breast"},{"key":"3556_CR59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.breast.2021.07.015","volume":"59","author":"S Cao","year":"2021","unstructured":"Cao S, Liu X, Cui J, Liu X, Zhong J, Yang Z, et al. Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3,578 patients. Breast. 2021;59:256\u201369.","journal-title":"Breast"},{"issue":"1","key":"3556_CR60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12282-019-00996-x","volume":"27","author":"A Nakagawa","year":"2020","unstructured":"Nakagawa A, Fujimoto H, Nagashima T, Sangai T, Takada M, Masuda T, et al. Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema. Breast Cancer. 2020;27(1):77\u201384.","journal-title":"Breast Cancer"},{"issue":"6-7","key":"3556_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.imbio.2017.10.050","volume":"223","author":"I Mitrofanova","year":"2018","unstructured":"Mitrofanova I, Zavyalova M, Riabov V, Cherdyntseva N, Kzhyshkowska J. The effect of neoadjuvant chemotherapy on the correlation of tumor-associated macrophages with CD31 and LYVE-1. Immunobiology. 2018;223(6\u20137):449\u201359.","journal-title":"Immunobiology"},{"key":"3556_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1471-2407-10-137","volume":"10","author":"M P\u00f6lcher","year":"2010","unstructured":"P\u00f6lcher M, Rudlowski C, Friedrichs N, Mielich M, H\u00f6ller T, Wolfgarten M, et al. In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer. BMC Cancer. 2010;10:137.","journal-title":"BMC Cancer"},{"issue":"2","key":"3556_CR63","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cell.2022.12.031","volume":"186","author":"L Biswas","year":"2023","unstructured":"Biswas L, Chen J, De Angelis J, Singh A, Owen-Woods C, Ding Z, et al. Lymphatic vessels in bone support regeneration after injury. Cell. 2023;186(2):382-97.e24.","journal-title":"Cell"},{"issue":"5","key":"3556_CR64","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.celrep.2016.09.083","volume":"17","author":"D Alishekevitz","year":"2016","unstructured":"Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, et al. Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Rep. 2016;17(5):1344\u201356.","journal-title":"Cell Rep"},{"issue":"1","key":"3556_CR65","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12885-018-4619-8","volume":"18","author":"AR Harris","year":"2018","unstructured":"Harris AR, Perez MJ, Munson JM. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression. BMC Cancer. 2018;18(1):718.","journal-title":"BMC Cancer"},{"issue":"12","key":"3556_CR66","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41419-019-2181-1","volume":"10","author":"A Zamora","year":"2019","unstructured":"Zamora A, Alves M, Chollet C, Therville N, Fougeray T, Tatin F, et al. Paclitaxel induces lymphatic endothelial cells autophagy to promote metastasis. Cell Death Dis. 2019;10(12):956.","journal-title":"Cell Death Dis"},{"issue":"10","key":"3556_CR67","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1364\/BOE.9.004631","volume":"9","author":"S Kwon","year":"2018","unstructured":"Kwon S, Velasquez FC, Sevick-Muraca EM. Near-infrared fluorescence lymphatic imaging in vascular endothelial growth factor-C overexpressing murine melanoma. Biomed Opt Express. 2018;9(10):4631\u20137.","journal-title":"Biomed Opt Express"},{"issue":"12","key":"3556_CR68","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.immuni.2021.11.003","volume":"54","author":"AE Overacre-Delgoffe","year":"2021","unstructured":"Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr AHP, Tometich JT, Bhattacharjee A, et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021;54(12):2812-24.e4.","journal-title":"Immunity"},{"issue":"9","key":"3556_CR69","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s42255-021-00457-w","volume":"3","author":"E Cao","year":"2021","unstructured":"Cao E, Watt MJ, Nowell CJ, Quach T, Simpson JS, De Melo FV, et al. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity. Nat Metab. 2021;3(9):1175\u201388.","journal-title":"Nat Metab"},{"issue":"12","key":"3556_CR70","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.immuni.2021.10.003","volume":"54","author":"RS Czepielewski","year":"2021","unstructured":"Czepielewski RS, Erlich EC, Onufer EJ, Young S, Saunders BT, Han YH, et al. Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor. Immunity. 2021;54(12):2795-811.e9.","journal-title":"Immunity"},{"key":"3556_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117428","volume":"320","author":"L Ou","year":"2024","unstructured":"Ou L, Liu HR, Shi XY, Peng C, Zou YJ, Jia JW, et al. Terminalia chebula Retz. aqueous extract inhibits the Helicobacter pylori-induced inflammatory response by regulating the inflammasome signaling and ER-stress pathway. J Ethnopharmacol. 2024;320:117428.","journal-title":"J Ethnopharmacol"},{"issue":"17","key":"3556_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37046","volume":"10","author":"L Ou","year":"2024","unstructured":"Ou L, Liu H, Peng C, Zou Y, Jia J, Li H, et al. Helicobacter pylori infection facilitates cell migration and potentially impact clinical outcomes in gastric cancer. Heliyon. 2024;10(17):e37046.","journal-title":"Heliyon"},{"issue":"5","key":"3556_CR73","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.4049\/jimmunol.1500686","volume":"197","author":"S Nayar","year":"2016","unstructured":"Nayar S, Campos J, Chung MM, Navarro-N\u00fa\u00f1ez L, Chachlani M, Steinthal N, et al. Bimodal expansion of the lymphatic vessels is regulated by the sequential expression of IL-7 and lymphotoxin \u03b11\u03b22 in newly formed tertiary lymphoid structures. J Immunol. 2016;197(5):1957\u201367.","journal-title":"J Immunol"},{"issue":"6","key":"3556_CR74","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1172\/JCI125044","volume":"129","author":"HO Reed","year":"2019","unstructured":"Reed HO, Wang L, Sonett J, Chen M, Yang J, Li L, et al. Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage. J Clin Invest. 2019;129(6):2514\u201326.","journal-title":"J Clin Invest"},{"issue":"12","key":"3556_CR75","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1073\/pnas.0606697104","volume":"104","author":"GC Furtado","year":"2007","unstructured":"Furtado GC, Marinkovic T, Martin AP, Garin A, Hoch B, Hubner W, et al. Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc Natl Acad Sci U S A. 2007;104(12):5026\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3556_CR76","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10238-024-01538-2","volume":"25","author":"H Liu","year":"2024","unstructured":"Liu H, Wang P. CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance. Clin Exp Med. 2024;25(1):21.","journal-title":"Clin Exp Med"},{"issue":"1","key":"3556_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314745","volume":"20","author":"H Liu","year":"2025","unstructured":"Liu H, Karsidag M, Chhatwal K, Wang P, Tang T. Single-cell and bulk RNA sequencing analysis reveals CENPA as a potential biomarker and therapeutic target in cancers. PLoS ONE. 2025;20(1):e0314745.","journal-title":"PLoS ONE"},{"issue":"3","key":"3556_CR78","first-page":"105","volume":"10","author":"RM Joshi","year":"2024","unstructured":"Joshi RM, Telang B, Soni G, Khalife A. Overview of perspectives on cancer, newer therapies, and future directions. Oncol Transl Med. 2024;10(3):105\u20139.","journal-title":"Oncol Transl Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03556-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:02:06Z","timestamp":1767045726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03556-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3556"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03556-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient information and tissue samples were collected according to the ethical guidelines set by the Internal Review Board of Sun Yat-Sen Memorial Hospital (approval number: SYSKY-2025-182-01). This study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients to permit researchers to analyze clinical features and tissue samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1263"}}